| Literature DB >> 31765717 |
Fehaid Alanazi1, Faith A A Kwa1, Genia Burchall1, Denise E Jackson2.
Abstract
Multiple myeloma (MM), a plasma cell malignancy, is characterised by lesions in multiple bones involving transformed, matured post-follicular B cells. The course of the disease involves an initial development of monoclonal gammopathy of undetermined significance (MGUS), followed by smouldering MM, before the full MM disease emerges. Despite novel therapies, MM remains incurable, managed by combination therapies, including proteasome inhibitors (PIs), immunomodulators (IMiDs) and anti-human CD38 (daratumumab). MM patients have an increased risk of thromboembolic events due to combination treatments with IMiDs, PIs and anti-human CD38 antibody, and steroids. This review will examine the efficacy and pro-thrombotic effects of MM therapies. CrownEntities:
Keywords: Aspirin (PubChem CID: 2244); Bortezomib (PubChem CID: 387447); Carfilzomib (PubChem CID: 11556711); Cyclophosphamide (PubChem CID: 2907); Daratumumab/Anti-CD38 (PubChem SID: 378174561); Dexamethasone (PubChem CID: 5743); Histone deacetylase (HDAC) inhibitors (PubChem CID: 10095659); Ixazomib (PubChem CID: 772); Lenalidomide (PubChem CID: 216326); Low molecular weight heparin (PubChem CID: 772); Panobinostat (PubChem CID: 6918837); Pomalidomide (PubChem CID: 134780); Thalidomide (PubChem CID: 5426)
Mesh：
Substances：
Year: 2019 PMID： 31765717 DOI： 10.1016/j.drudis.2019.11.008
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851